Xtant Medical Holdings (XTNT) Depreciation & Amortization (CF) (2010 - 2025)

Xtant Medical Holdings (XTNT) has reported Depreciation & Amortization (CF) for 16 consecutive years, with $1.2 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Depreciation & Amortization (CF) rose 8.2% year-over-year to $1.2 million; the TTM figure through Dec 2025 stood at $3.4 million (down 19.41% YoY), while the FY2024 annual figure was $4.2 million, up 33.08% from the prior year.
• Depreciation & Amortization (CF) retreated to $1.2 million in Q3 2025 per XTNT's latest filing, from $1.2 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $1.2 million in Q2 2025 and bottomed at $281000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $706631.6 across 5 years, with a median of $803000.0 in 2023.
• Annual changes were most pronounced in 2021 — Depreciation & Amortization (CF) plunged 45.26% — and 2023, when it surged 216.82%.
• Xtant Medical Holdings' Depreciation & Amortization (CF) stood at $291000.0 in 2021, then increased by 10.31% to $321000.0 in 2022, then soared by 216.82% to $1.0 million in 2023, then advanced by 12.88% to $1.1 million in 2024, then advanced by 1.13% to $1.2 million in 2025.
• Business Quant data shows XTNT's Depreciation & Amortization (CF) at $1.2 million in Q3 2025, $1.2 million in Q2 2025, and $1.1 million in Q1 2025.